Clinical Trial on Smoking Cessation Medications
Overview of the Study
A clinical trial was conducted to assess the safety of the three most commonly prescribed medications for quitting smoking: nicotine-replacement therapy, varenicline, and bupropion. Cigarette smoking significantly contributes to cardiovascular disease, increasing the risk of heart attack, stroke, peripheral vascular diseases, atrial fibrillation, sudden cardiac death, exacerbated heart failure, and a heightened likelihood of blood clots following revascularization. The US Public Health Service Clinical Practice Guidelines for Smoking Cessation advocate for healthcare providers to offer both behavioral support and pharmacological treatments to assist patients in quitting smoking.
Common Medications for Quitting Smoking
The three primary medications utilized in smoking cessation are:
– Nicotine-replacement therapy (Nicoderm, Nicorette, Habitrol)
– Varenicline (Champix or Chantix)
– Bupropion (Zyban)
All three medications can influence cardiovascular health. Nicotine is known to elevate heart rate, blood pressure, and cardiac workload. Bupropion may similarly increase heart rate and blood pressure, while varenicline could impact the function and regeneration of cells lining blood vessel walls, potentially leading to adverse cardiac events.
Research Methodology
Researchers from the Department of Medicine at the University of California carried out a randomized clinical trial to evaluate and compare the cardiac effects of these three medications. The findings were published in JAMA Internal Medicine. The study utilized existing clinical data from an earlier investigation and extended the trial, known as EAGLES (Evaluating Adverse Events in a Global Smoking Cessation Study), to monitor patients for up to 52 weeks.
Investigating Drug Differences
The primary outcome examined was the occurrence of a major adverse cardiac event (MACE), defined as cardiovascular death, non-fatal heart attack, or non-fatal stroke. Secondary outcomes included the occurrence of MACE+—which encompassed any MACE, new or worsening peripheral vascular disease, coronary artery bypass, or hospitalization due to inadequate blood flow and oxygen to the heart. The analysis involved over 4,000 patients.
During the 12-week treatment phase and follow-up, no significant differences were observed between the treatment groups regarding the time to experience a MACE. Comparisons among the three medications for MACE+ also revealed no significant differences. When contrasting nicotine-replacement therapy with a placebo for the time to MACE and MACE+, no noteworthy differences were identified.
Patients with high cardiovascular risk scores at the study’s commencement exhibited the highest risk of cardiovascular events throughout the trial. However, there were no differences in cardiovascular event incidence among treatment groups when categorized by low, medium, and high cardiovascular risk scores. A limitation of the study was the exclusion of patients with unstable cardiovascular conditions, which means the results may not be applicable to this demographic.
Conclusion
In summary, the medications studied for smoking cessation appear to be both safe and effective. Healthcare providers are encouraged to continue offering counseling and pharmacological options for patients interested in quitting smoking, as the cardiovascular advantages of cessation significantly surpass the potential side effects associated with these medications.
Reference
Benowitz NL, Pipe A, West R, et al. Cardiovascular safety of varenicline, bupropion, and nicotine patch in smokers: A randomized clinical trial. JAMA Intern Med. 2018. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2677060